Improving future equitable access to new and innovative cancer screenings among Medicare beneficiaries – ACS CAN
American Cancer Society Cancer Action Network (ACS CAN) shared a post on LinkedIn:
“The MCEDAct was introduced in the U.S. House and Senate last week! This bipartisan legislation aims to improve future equitable access to new and innovative cancer screenings among Medicare beneficiaries in order to increase early detection of more cancers for more individuals.
‘The evidence overwhelmingly supports that detecting cancer earlier can be the difference between life and death,’ says Lisa A. Lacasse, president of American Cancer Society Cancer Action Network (ACS CAN). ‘When cancer is detected at an earlier stage, it is often easier and less costly to treat, and patients are more likely to survive.
We also know that the risk of developing cancer increases with age as do the odds of developing an invasive form of cancer. This legislation, for which ACS CAN has long advocated, creates a pathway to ensure timely Medicare coverage of new, innovative multi-cancer screening tests after FDA approval and clinical benefit has been shown.
This legislation can greatly expand access to early detection.’
Lisa Lacasse, President of ACS CAN, shared this post, adding:
“Congress, now is the time! More than 2 million people in America are expected to be diagnosed with cancer and over 1 million of those cases are expected to be in individuals over the age of 65.
We have long advocated for this legislation creates a pathway to ensure timely Medicare coverage of new, innovative multi-cancer screening tests after FDA approval and clinical benefit has been shown.”
More posts featuring ACS CAN and Lisa Lacasse.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023